



## Arbutus to Present at the 2018 Webbush PacGrow Healthcare Conference

August 9, 2018

WARMINSTER, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus' Chief Scientific Officer, will present a corporate update at the Webbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30 pm – 3:00 pm ET in New York.

A live webcast of the presentation can be accessed through the Investor section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com). A replay of the webcast will be available for 90 days following the live presentation.

### About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### Investors

Mark Murray  
President and CEO  
Phone: 604-419-3200  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

Pam Murphy  
Investor Relations Consultant  
Phone: 604-419-3200  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

 [Primary Logo](#)

Source: Arbutus Biopharma Corporation